- Fecal Incontinence
|Investigating the Crime Scene-Molecular Signatures in Inflammatory Bowel Disease
Int J Mol Sci. 2023 Jul 7;24(13):11217. doi: 10.3390/ijms241311217.
1Molecular Diagnostic and Clinical Research Unit, University Hospital of Southern Denmark, Institute of Regional Research, University of Southern Denmark, 5000 Odense, Denmark.
2Institute of Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark.
3Medical Microbiology and Immunology, Department of Health Science and Technology, Aalborg University, 9000 Aalborg, Denmark.
4Institute for Clinical Molecular Biology, Christian-Albrecht's University, 24105 Kiel, Germany.
5Department of Medicine, Université de Montréal, Montreal, QC H3C 3J7, Canada.
6Montreal Heart Institute Research Institute, Montreal, QC H1T 1C8, Canada.
7Department of Gastroenterology, Keio University School of Medicine, Tokyo 160-8582, Japan.
8Experimental Animal Models, Department of Veterinary and Animal Sciences, University of Copenhagen, 1870 Frederiksberg, Denmark.
9Department of Gastroenterology, Herlev Hospital, University of Copenhagen, 2730 Herlev, Denmark.
Inflammatory bowel diseases (IBD) are without cure and troublesome to manage because of the considerable diversity between patients and the lack of reliable biomarkers. Several studies have demonstrated that diet, gut microbiota, genetics and other patient factors are essential for disease occurrence and progression. Understanding the link between these factors is crucial for identifying molecular signatures that identify biomarkers to advance the management of IBD. Recent technological breakthroughs and data integration have fuelled the intensity of this research. This research demonstrates that the effect of diet depends on patient factors and gut microbial activity. It also identifies a range of potential biomarkers for IBD management, including mucosa-derived cytokines, gasdermins and neutrophil extracellular traps, all of which need further evaluation before clinical translation. This review provides an update on cutting-edge research in IBD that aims to improve disease management and patient quality of life.